SUSD2 as a Radioligand Therapy Target
SUSD2, sushi domain containing 2, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, SUSD2 staining is highest in testicular cancer (100% of samples positive), ovarian cancer (100% of samples positive) and thyroid cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is SUSD2 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in testicular cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
SUSD2 expression in cancer
Protein expression of SUSD2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Testicular Cancer | 0.88 | High | 100% |
| Ovarian Cancer | 0.67 | High | 100% |
| Thyroid Cancer | 0.58 | High | 100% |
| Head and Neck Cancer | 0.50 | Medium | 100% |
| Breast Cancer | 0.48 | Medium | 91% |
| Lung Cancer | 0.47 | Medium | 100% |
| Cervical Cancer | 0.42 | Medium | 100% |
| Endometrial Cancer | 0.42 | Medium | 91% |
| Bladder Cancer | 0.42 | Medium | 100% |
| Pancreatic Cancer | 0.42 | Medium | 92% |
| Skin Cancer | 0.36 | Medium | 100% |
| Gastric Cancer | 0.33 | Medium | 91% |
| Melanoma | 0.31 | Medium | 67% |
| Neuroendocrine Tumors | 0.25 | Medium | 75% |
| Liver Cancer | 0.25 | Medium | 58% |
| Colorectal Cancer | 0.22 | Medium | 67% |
| Prostate Cancer | 0.18 | Low | 55% |
| Glioma | 0.17 | Low | 50% |
| Kidney Cancer | 0.14 | Low | 42% |
| Lymphoma | 0.11 | Low | 33% |
Is SUSD2 internalized?
Nuclens has not yet extracted internalization evidence for SUSD2. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
SUSD2 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for SUSD2 yet. Search ClinicalTrials.gov for SUSD2 trials.
SUSD2 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SUSD2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
SUSD2 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.09 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related testicular cancer radioligand targets
HER3 (ERBB3) · c-MET (MET) · STEAP2 · KIT · SSTR2 · TMEFF2 · Mesothelin (MSLN) · HER2 (ERBB2)
See all radioligand therapy targets in testicular cancer.
See how SUSD2 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.